Nomad Power Solutions Inc. (NMAD) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Nomad Power Solutions Inc. (NASDAQ: NMAD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.47 (-2.53% 1D, market cap $55.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NMAD ranks #766 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NMAD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and BOLD (Boundless Bio Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M). Among the 5-stock peer group, NMAD leads on earnings multiple (N/A) while NMAD leads on capital efficiency (-35.0% ROIC).
Per NMAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001335105), Nomad Power Solutions Inc. generated $14.3M in revenue (+43.0% YoY), -$6.1M in net income, and -$3.1M in free cash flow against $12.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NMAD currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.85) and Max Pain ($3.64) forces dealer call-delta covering toward $8.80.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Nomad Power Solutions Inc. (NMAD) dropped -2.53% to $3.47, trading at 18% of its 52-week range ($2.36 – $8.38). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Utility Specialists and Elgin B. Robertson extend coverage across Southeast and South Central U.S. through performance-based sales relationships BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions,
NOMAD Power Solutions, Inc. (Nasdaq: NMAD) ("NOMAD" or the "Company"), a provider of transportable, utility-grade battery energy storage systems ("BESS") through its wholly owned subsidiary NOMAD
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +43.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NMAD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NMAD. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Nomad Power Solutions Inc. (NMAD) ranks #766 by composite RQD confidence (31/100, grade E) and #724 by equity capitalization ($55.9M). Within this direct 5-issuer industry benchmark cohort, NMAD leads on earnings valuation at N/A trailing P/E, while NMAD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NMAD at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NMAD
ACTIVE
Nomad Power Solutions Inc. | E | 31/100 | — | — | -35.0% | -2.53% | $55.9M | Benchmark Subject |
| HRTX Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | +6.27% | $56.0M | /hrtx-vs-nmad → |
| BOLD Boundless Bio Inc. | D | 46/100 | — | — | -35.0% | -1.22% | $56.4M | /bold-vs-nmad → |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | +7.24% | $55.2M | /ctor-vs-nmad → |
| VRCA Verrica Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | -4.18% | $55.1M | /vrca-vs-nmad → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nomad Power Solutions Inc. (NMAD) reported GAAP revenue of $14.3M (+43.0% vs. FY2024 revenue of $10.0M , and +0.3% cumulative change since FY2023) , GAAP net income of -$6.1M, operating cash flow of -$3.1M, and free cash flow of -$3.1M (+3.0% YoY). On the balance sheet, NMAD closed FY2025 with $12.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.3M | -$6.1M | -$3.1M | -$3.1M | $12.7M | — |
| FY2024 (FY) | 2024-12-31 | $10.0M | -$3.6M | -$3.2M | -$3.2M | $1.1M | — |
| FY2023 (FY) | 2023-12-31 | $14.3M | -$5.1M | -$4.3M | -$4.3M | — | — |
As of 2026-11-03, Nomad Power Solutions Inc. (NASDAQ: NMAD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.47 (-2.53% 1D, market cap $55.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NMAD ranks #766 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NMAD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and BOLD (Boundless Bio Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M). Among the 5-stock peer group, NMAD leads on earnings multiple (N/A) while NMAD leads on capital efficiency (-35.0% ROIC).
Per NMAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001335105), Nomad Power Solutions Inc. generated $14.3M in revenue (+43.0% YoY), -$6.1M in net income, and -$3.1M in free cash flow against $12.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
NMAD last traded at $3.47 (-2.53% on volume of 281,163 shares), positioning the stock -9.87% below its 50-day simple moving average ($3.85) and -18.54% below its 200-day simple moving average ($4.26). Across its 52-week range of $2.36 to $8.38, NMAD sits at the 18.4% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.04 to $3.90).
Nomad Power Solutions Inc. (NMAD) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.47 (-2.53% 1D, market capitalization $55.9M).
Nomad Power Solutions Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Recent news items describe customer orders and sales reach, but these are headlines without financial detail in the source data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nomad Power Solutions Inc. (NMAD) reported $14.3M in annual revenue (up from $10.0M in FY2024, +43.0% YoY) and -$6.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.3M revenue, -$5.1M net income) through FY2025, NMAD scaled operating cash flow to -$3.1M and free cash flow to -$3.1M, backed by $12.7M in total assets against $0 in total debt.
Upstream and downstream dependencies cannot be mapped from source data. Sector correlations are not provided beyond the Health Care classification. A prospective investor should watch whether the reported customer orders and manufacturing expansion convert into revenue, since that conversion is the only identifiable second-order link in the source data and it is not verifiable here.
Real-time company headlines, analyst actions, and sector developments for Nomad Power Solutions Inc. (NMAD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nomad Power Solutions Inc. (NMAD) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in NMAD in my $100K Virtual Cash book at $3.56. Headlines report more than $30 million in customer orders and expanded manufacturing capacity, a potential catalyst if it converts to revenue.. Trading inside a $2.36–$8.38 52-week range with -5.39% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@BreakoutHunter Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.56 and keeping dry powder in case we test $3.31.
The company reported $0.0M revenue and negative free cash flow in each of FY 2023–FY 2025 with an RQD score of 33 (E).. Look at the math on NMAD: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $3.13 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: